<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1577">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03086343</url>
  </required_header>
  <id_info>
    <org_study_id>M15-925</org_study_id>
    <secondary_id>2016-000933-37</secondary_id>
    <nct_id>NCT03086343</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Compare ABT-494 to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs</brief_title>
  <acronym>SELECT-CHOICE</acronym>
  <official_title>A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing ABT-494 to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The comparison of safety and efficacy of ABT-494 versus abatacept in participants with
      rheumatoid arthritis on a stable background conventional synthetic Disease Modifying
      Anti-Rheumatic Drug (csDMARD) who have an inadequate response or intolerance to biologic
      DMARDs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) (non-inferiority)</measure>
    <time_frame>At week 12</time_frame>
    <description>The Disease Activity Score (DAS)28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) (superiority)</measure>
    <time_frame>At week 12</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants achieving Disease Activity Score (DAS) 28 based Clinical Remission (CR)</measure>
    <time_frame>At week 12</time_frame>
    <description>Proportion of participants achieving Clinical Remission (CR) as defined by a clinical response Disease Activity Score (DAS)28 C-Reactive Protein (CRP) less than 2.6. The DAS28 is a validated index of rheumatoid arthritis disease activity. Scores on the DAS28 range from 0 to 10. A DAS28 score greater than 5.1 indicates high disease activity, a DAS28 score less than or equal to 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates CR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ABT-494</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily for 24 weeks during Period 1 and up to 5 years during Period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abatacept followed by ABT-494</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous (IV) infusion of abatacept at Baseline, Week 2, Week 4, Week 8, Week 12, Week 16 and Week 20 followed by ABT-494 starting at week 24 up to 5 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494</intervention_name>
    <description>Oral Tablet</description>
    <arm_group_label>ABT-494</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Abatacept followed by ABT-494</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494 matching placebo</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Abatacept followed by ABT-494</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept matching placebo</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>ABT-494</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of rheumatoid arthritis (RA) for &gt;= 3 months.

          -  Participants have been treated for &gt;= 3 months with &gt;= 1 bDMARD therapy, but continue
             to exhibit active RA or had to discontinue due to intolerability or toxicity,
             irrespective of treatment duration and have never received abatacept prior to the
             first dose of study drug.

          -  Participants have been receiving csDMARD therapy &gt;= 3 months and on a stable dose for
             &gt;= 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed:
             methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.
             A combination of up to two background csDMARDs is allowed except the combination of
             MTX and leflunomide.

          -  Meets the following criteria: &gt;= 6 swollen joints (based on 66 joint counts) and &gt;= 6
             tender joints (based on 68 joint counts) at Screening and Baseline Visits and hsCRP
             &gt;= 3 mg/L at Screening .

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             ABT-494, tofacitinib, baricitinib and filgotinib).

          -  Prior exposure to abatacept

          -  History of any arthritis with onset prior to age 17 years or current diagnosis of
             inflammatory joint disease other than RA. Current diagnosis of secondary Sjogren's
             Syndrome is permitted

          -  Laboratory values meeting the following criteria within the Screening period prior to
             the first dose of study drug: serum aspartate transaminase &gt; 2 × upper limit of
             normal (ULN); serum alanine transaminase &gt; 2 × ULN; estimated glomerular filtration
             rate by simplified 4-variable Modification of Diet in Renal Disease formula &lt; 40
             milli liter (mL)/minute/1.73 meter (m)^2; total white blood cell count &lt; 2,500/micro
             liter (μL); absolute neutrophil count &lt; 1,500/μL; platelet count &lt; 100,000/μL;
             absolute lymphocyte count &lt; 800/μL; and hemoglobin &lt; 10 g/ deciliter (dL).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847.283.8955</phone>
  </overall_contact>
  <location>
    <facility>
      <name>CHI St. Vincent Medical Group Hot Springs /ID# 154561</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc. /ID# 154576</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research of Orlando /ID# 154580</name>
      <address>
        <city>Winter Garden</city>
        <state>Florida</state>
        <zip>34787</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Associates of New Mexico /ID# 154560</name>
      <address>
        <city>Las Cruces</city>
        <state>New Mexico</state>
        <zip>88011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research /ID# 154572</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates of Kingsport /ID# 154548</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Belo Horizonte /ID# 154631</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cmip-Centro Mineiro de Pesquisa /Id# 154564</name>
      <address>
        <city>Juiz de Fora, Minas Gerais</city>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa em Reumatologia da UNIFESP /ID# 154563</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04039-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CEMEC Centro Multidisciplinar de Estudios Clinicos /ID# 154632</name>
      <address>
        <city>Sao Paulo</city>
        <zip>09190-510</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedoes /Id# 155228</name>
      <address>
        <city>Vitoria</city>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Vittorio Emanuele /ID# 161172</name>
      <address>
        <city>Catania</city>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST G. Pini /ID# 162223</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco /ID# 161150</name>
      <address>
        <city>Milan</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 20, 2017</lastchanged_date>
  <firstreceived_date>March 20, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis</keyword>
  <keyword>Joint Disease</keyword>
  <keyword>Musculoskeletal Disease</keyword>
  <keyword>Anti-inflammatory agents</keyword>
  <keyword>Antirheumatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
